Lanatoside C Cardiotoxicity Evaluation in Cardiomyocytes and Mice

A study evaluating the cardiotoxicity of the anti-cancer drug Lanatoside C at concentrations of 50–200 nM in human AC16 cardiomyocytes and a dose of 80 mg/kg/day in male BALB/c mice over 28 days. The dataset, authored by Yu-Hai Ma and shared under CC-BY-4.0, includes results from cell viability assays, flow cytometry, echocardiography, and histopathological analysis. It was last updated on 2026-05-24.

Use Cases

• Modeling dose-dependent cardiotoxicity based on in vitro cell viability and apoptosis data.
• Investigating mitochondrial-dependent apoptotic pathways based on measurements of ROS, cytochrome C, and caspase activity.
• Correlating in vitro cytotoxicity with in vivo cardiac function impairment based on echocardiography parameters LVEF and LVFS.

Strengths

• Data includes results from multiple complementary assays: cell viability, flow cytometry, Western blot, and echocardiography.
• Study evaluates both cellular (50–200 nM) and in vivo (80 mg/kg/day for 28 days) effects, providing a multi-level assessment.
• The dataset is shared under a permissive CC-BY-4.0 license, allowing for broad reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small (365.4 KB), indicating limited scope.

Provenance

Source

Yu-Hai Ma

Collection Method

Experimental study using human AC16 cardiomyocytes and male BALB/c mice, employing assays including cell viability tests, flow cytometry, and echocardiography.

Freshness

Last updated 2026-05-24 22:01:25; freshness should be verified.